James Lindsay

Title: Dr
Reader in Inflammatory Bowel Disease, Consultant Gastroenterologist

 Dr James Lindsay is Consultant Gastroenterologist at Barts Health NHS Trust and Reader in Inflammatory Bowel Disease at Barts and the London School of Medicine.

Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital.




Dr Lindsay is the E-learning ambassador for the European Crohn’s and Colitis Organisation (ECCO), and past chair of the ECCO education committee. He has chaired working groups for the ECCO consensus on the management of Crohn’s disease and ulcerative colitis. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology (UEG).

He also serves on the BSG IBD Clinical Trials Steering Group and is Chief Investigator for a series of investigator-led and commercial clinical trials in IBD. In addition, he collaborates with two translational research programmes: one focuses on the antigen presentation within the mucosal immune system, and the other studies the role microRNA profiles to direct phenotype in IBD.


Dr James Lindsay's recent and ongoing translational science projects funded by peer-reviewed grants are as follows:


  • Assessment of IL-10 responsiveness of antigen presenting cells in patients with IBD


  • The aryl hydrocarbon receptor as a link between environmental triggers and intestinal immune regulation in Inflammatory Bowel Disease (IBD)


  • Human colonic T-cell responses in Crohn’s disease: modulation by non-peptide phosphoantigen products of the gut microbiota


  • Vedolizumab: assessing impact on α4β7+ unconventional T-cells and α4β7+ precursors of intestinal antigen presenting cells


  • Role of miRNA is assessing response to autologous bone marrow transplantation: the ASTIC trial


  • Histone deacetylases and their regulation by microRNAs as novel therapeutic targets for fibrosis in Crohn’s Disease


  • Selective histone deacetylase inhibitors for treatment of inflammatory bowel diseases


  • Targeting the Wnt signalling pathway in Crohn's disease: evaluations of regulatory microRNAs in a model 3D culture system


  • Measuring the burden of food‐related quality of life in inflammatory bowel disease: developing and testing interventions that are relevant to, and designed by, people with IBD (in collaboration with Kings College London)

Group Members


In Collaboration with Dr Andrew Stagg, Dr Lindsay's Research members are:

Dr Neil Mcarthy

Dr Paul Harrow

Ms. Inva Hoti


And in Collaboration with Prof Andrew Silver

Dr Amy Lewis

Dr Anke Nijhuis

Dr Carla Felice



Dr Lindsay's most recent publication are:

Giles EM, Sanders TJ, McCarthy NE, Lung J, Pathak M, MacDonald TT, Lindsay JO, Stagg AJ. Regulation of human intestinal T-cell responses by Type 1 Interferon-STAT1 signalling is disrupted in inflammatory bowel disease.  Mucosal Immunology, 2016 May 25. doi: 10.1038/mi.2016.44

Hawkey CJ, (Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G), Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel JF, Jouet JP, Clark E, Saccardi R, Tyndall A, Travis S, Farge D.  Autologous haemopoetic stem cell transplantation for refractory crohn disease: a randomised clinical trial. JAMA. 2015 Dec 15; 314(23):2524-34

McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM, Wildemann M, Bashir Z, Whelan K, Sanderson I, Lindsay JO, Stagg AJ. Colonic Vδ2+ T-cells display elevated TNF production and reversible ablation by azathioprine therapy in Crohn’s disease. Journal of Clinical Investigation, 2015 Aug 3;125(8):3215-25. doi: 10.1172/JCI80840

Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K. Siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota. Gut, 2016 Jun;65(6):944-53.

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, Annese V, Bampton P, Barnardo M, Bell S, Cole A, Connor SJ, Creed T, Cummings FR, D'Amato M, Daneshmend TK, Fedorak RN, Florin TH, Gaya DR, Greig E, Halfvarson J, Hart A, Irving PM, Jones G, Karban A, Lawrance IC, Lee JC, Lees C, Lev-Tzion R, Lindsay JO, Mansfield J, Mawdsley J, Mazhar Z, Parkes M, Parnell K, Orchard TR, Radford-Smith G, Russell RK, Reffitt D, Satsangi J, Silverberg MS, Sturniolo GC, Tremelling M, Tsianos EV, van Heel DA, Walsh A, Watermeyer G, Weersma RK, Zeissig S, Rossjohn J, Holden AL; International Serious Adverse Events Consortium; IBD Pharmacogenetics Study Group, Ahmad T. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014 Oct;46(10):1131-4


View all James Lindsay's Research Publications at: http://www.researchpublications.qmul.ac.uk


Consultant Gastroenterologist

Bart's Health NHS Trust,

The Royal London Hospital,

London, E1 1BB

United Kingdom,

Tel: +44 (0) 20 3954 3300



Reader in Inflammatory Bowel Disease

Centre for Immunobiology

Blizard institute, Barts and the London School of Medicine Queen Mary University of London

4 Newark Street, London E1 2AT

United Kingdom

Tel +44 (0) 20 7882 7191



020 3594 3300
This email address is being protected from spambots. You need JavaScript enabled to view it.